Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of MK-1092 in Healthy Subjects and Diabetes
NCT03170544Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2017
- Primary completion
- Nov 2018
- Modality
- Small Molecules, Insulin and Analogs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mk-1092 in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (14 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experienced an Adverse Event (AE) up to 112 days, Number of Participants Who Discontinued the Study Due to an AE up to 58 days and 1 more. Started Aug 2017; status: completed.
02
Drugs
mk-1092
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03170544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03170544.